Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.57 |
| ▸ | PPIA | P62937 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6566692 | 0.89 | MEN1 (0.61) | KMT2AMEN1LRRK2PPIASGMS2 | |
| SCHEMBL6567641 | 0.88 | PPIA (0.55) | KMT2AMEN1LRRK2PPIASGMS2 | |
| SCHEMBL6566664 | 0.84 | MEN1 (0.57) | KMT2AMEN1LRRK2PPIASGMS2 | |
| SCHEMBL6564693 | 0.83 | LRRK2 (0.57) | KMT2AMEN1LRRK2PPIAL3MBTL1 | |
| SCHEMBL6566900 | 0.83 | MEN1 (0.56) | KMT2AMEN1PPIAKDM4ESGMS2 | |
| SCHEMBL6566726 | 0.83 | MEN1 (0.56) | KMT2AMEN1LRRK2PPIASGMS2 | |
| SCHEMBL6568084 | 0.82 | PPIA (0.60) | KMT2AMEN1LRRK2PPIASGMS2 | |
| SCHEMBL6566043 | 0.82 | LRRK2 (0.56) | KMT2AMEN1LRRK2PPIASGMS2 | |
| SCHEMBL6567594 | 0.82 | MEN1 (0.61) | KMT2AMEN1LRRK2PPIASGMS2 | |
| SCHEMBL6565756 | 0.82 | MEN1 (0.56) | KMT2AMEN1LRRK2PPIASGMS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | KMT2A 3137/4885MEN1 4143/4885LRRK2 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.